Overview
Paul Ehrlich transformed medicine by proving that chemicals could selectively target disease-causing microbes without harming human cells—a radical idea he called the “magic bullet.” Between 1877 and 1915 he synthesized over 600 arsenical compounds, culminating in 1909 with compound 606 (Salvarsan), the first effective treatment for syphilis. Simultaneously, his meticulous staining techniques revealed the cellular universe of blood, distinguishing red cells, white cells and platelets for the first time and laying the groundwork for clinical hematology. Ehrlich’s fusion of organic chemistry, microscopy and immunology created the interdisciplinary template for today’s drug-discovery pipelines.Ehrlich’s legacy extends beyond any single discovery. He introduced quantitative methods to immunology, showing that antitoxin levels could be measured in “Ehrlich units,” and he defined the side-chain theory (1897) that prefigured our modern understanding of receptors. By 1910, Salvarsan had treated >10 000 syphilis patients worldwide, slashing mortality and proving that systematic chemical modification could yield life-saving drugs—a principle that still drives pharmaceutical research.
History/Background
Born 14 March 1854 in Strehlen, Silesia (now Strzelin, Poland), Ehrlich was influenced by cousin Karl Weigert, a pathologist who introduced him to aniline dyes. While studying medicine at the Universities of Breslau, Strasbourg and Leipzig, Ehrlich spent nights in makeshift labs testing textile dyes on animal tissues. His 1878 doctoral thesis “Contributions to the Theory and Practice of Histological Staining” already described the selective affinity of dyes for cellular structures—an observation that would guide his later receptor concept.In 1890 Robert Koch invited Ehrlich to Berlin’s Institute for Infectious Diseases; there he joined Emil von Behring to standardize diphtheria antitoxin, creating the first immune serum therapy. Appointed director of Berlin’s Royal Institute for Experimental Therapy (1899) and later the Georg Speyer House (1906), Ehrlich led teams that screened 606 arsenobenzene derivatives before the 606th—dihydroxy-diamino-arsenobenzene—showed potent spirochetal activity. Marketed as Salvarsan on 19 September 1910, it was the world’s first blockbuster drug. Ehrlich died 20 August 1915 aged 61, his immune system weakened by the very compounds he had pioneered.
Key Information
- Gram staining modification (1882): Ehrlich added aniline-water gentian violet and iodine solution, stabilizing the dye-iodine complex inside Gram-positive bacteria; this tweak remains standard in microbiology labs today.- Blood-cell differentiation (1879-1886): Using mixtures of acidic and basic dyes, Ehrlich identified neutrophils, eosinophils, basophils, lymphocytes and the nucleated red-cell precursors that define pernicious anemia, leukemia and lymphoma.
- Side-chain theory (1897): Proposed that cells carry “side chains” (receptors) that bind toxins; excess chains are shed into blood as antibodies—an idea vindicated decades later by crystallography.
- Standardization of antisera: Introduced the “Lf” (Limes flocculating) unit, enabling reproducible antitoxin doses and saving thousands of diphtheria patients.
- Chemotherapy index: Coined the term “chemotherapy” and insisted on measuring the therapeutic index (toxic dose vs. curative dose), insisting that a useful drug must have an index ≥5.
- Nobel Prize: Shared the 1908 Nobel Prize in Physiology or Medicine with Élie Metchnikoff “for work on immunity.”
- Patent controversy: Refused to patent Salvarsan, arguing that medicine should benefit humanity; nonetheless, the Hoechst company trademarked the name and reaped millions.
